April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Anti-Angiogenic Effect of Fidarestat on Laser-Induced Choroidal Neovascularization in Mice
Author Affiliations & Notes
  • Miho Nozaki
    Department of Ophthalmology, Nagoya City Univ Medical School, Nagoya, Japan
  • Atsushi Nakajima
    Department of Pharmacology, Pharmaceutical Research Laboratories, Sanwa Kagaku Kenkyusho Co., Ltd., Inabe, Japan
  • Nobutaka Morimoto
    Department of Pharmacology, Pharmaceutical Research Laboratories, Sanwa Kagaku Kenkyusho Co., Ltd., Inabe, Japan
  • Noriaki Kato
    Department of Pharmacology, Pharmaceutical Research Laboratories, Sanwa Kagaku Kenkyusho Co., Ltd., Inabe, Japan
  • Yuichiro Ogura
    Department of Ophthalmology, Nagoya City Univ Medical School, Nagoya, Japan
  • Footnotes
    Commercial Relationships  Miho Nozaki, None; Atsushi Nakajima, Sanwa Kagaku Kenkyusho Co., Ltd. (E); Nobutaka Morimoto, Sanwa Kagaku Kenkyusho Co., Ltd. (E); Noriaki Kato, Sanwa Kagaku Kenkyusho Co., Ltd. (E); Yuichiro Ogura, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1788. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Miho Nozaki, Atsushi Nakajima, Nobutaka Morimoto, Noriaki Kato, Yuichiro Ogura; Anti-Angiogenic Effect of Fidarestat on Laser-Induced Choroidal Neovascularization in Mice. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1788.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Anti- vascular endothelial growth factor (VEGF) therapy is now standard of care for age-related macular degeneration (AMD), but this treatment requires repetitive vitreous injections for an indefinite period. Recently, it has been reported that the oral anti-cytokine therapy with Fidarestat is useful for prevention of choroidal neovascularization via a suppression of pro-inflammatory cytokine expression. The purpose of this study was to evaluate the anti-angiogenic effect of fidarestat on laser-induced choroidal neovascularization (CNV) model in mice.

Methods: : CNV was induced by laser injury in C57BL/6J mice, and CNV volumes were measured 7 days later by confocal evaluation of Griffonia simplicifolia Isolectin B4 staining of RPE-choroid flatmounts. The treatment groups were divided as follows: control (Arabic gum oral administration), Fidarestat (4-32mg/kg/day) oral administration (group F), anti-VEGF neutralizing antibody (nAb) (2 or 10 ng) vitreous injection (group V), both Fidarestat (32mg/kg/day) oral administration and anti-VEGF nAb (2 or 10 ng) vitreous injection (group F+V). And gGroup F, group V and group F+V were also divided as follows: start treatment just after laser (group-d0) and start treatment 3 days after laser (group-d3).

Results: : Oral administration of Fidarestat suppressed CNV volume in dose-dependent manner. Although group V (2ng)-d0 did not show significant suppression in CNV volume, group F+V (2ng) -d0 showed significant suppression in CNV volume (p<0.001). In group F-d3 and group V-d3, there is no significant suppression in CNV volume, but group F+V-d3 suppressed CNV volume significantly (p<0.05 for VEGF nAb 2ng, p<0.01 for 10ng).

Conclusions: : Conclusions: Fidarestat has proven safe in human. Oral administration of Fidarestat showed significant suppression of CNV, and anti-angiogenic effect was reinforced with anti-VEGF nAbs therapy. From our results, oral Fidarestat therapy might reduce the number of vitreous injections in anti-VEGF therapy for AMD.

Keywords: age-related macular degeneration • cytokines/chemokines • neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×